Drug/Drug Class: Corlanor Clinical Edit
First Implementation Date: December 3, 2018
Revised Date: April 28, 2022
Prepared for: MO HealthNet
Prepared by: MO HealthNet/Conduent
Criteria Status: ☐ Existing Criteria
☒ Revision of Existing Criteria
☐ New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Corlanor® (ivabradine)

Why Issue Selected: Corlanor® (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker used in stable symptomatic heart failure. It is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. In 2019, Corlanor also received an indication for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older. Corlanor should not be used as a substitute for beta blockers unless the patient is on maximally tolerated doses of beta blockers or if beta blockers are contraindicated. Currently there is much more evidence for beta blockers in heart failure than for Corlanor. Beta blockers have been shown to decrease death due to heart failure, cardiovascular death, and all-cause mortality while Corlanor has only been shown to decrease death due to heart failure. Given the well-proven mortality benefits of beta-blocker therapy, it is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of initiation of Corlanor therapy.

Program-Specific Information:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Claims</th>
<th>Spend</th>
<th>Average Spend per Claim</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORLANOR 5 MG TABLET</td>
<td>592</td>
<td>$248,123.39</td>
<td>$419.12</td>
</tr>
<tr>
<td>CORLANOR 7.5 MG TABLET</td>
<td>151</td>
<td>$72,488.24</td>
<td>$480.05</td>
</tr>
<tr>
<td>CORLANOR 5 MG/5 ML SOLN</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Type of Criteria: ☐ Increased risk of ADE
☒ Appropriate Indications
☐ Preferred Drug List
☒ Clinical Edit

Data Sources: ☐ Only Administrative Databases
☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Corlanor® (ivabradine)
• Age range: All appropriate MO HealthNet participants aged 6 months and older

**Approval Criteria**

- Documented history of Corlanor therapy in the past 60 days OR
- Prescribed by or in consultation with a cardiologist or other specialist for the treated disease state AND
- Participant aged ≥ 6 months and < 18 years:
  - Documented diagnosis of heart failure due to dilated cardiomyopathy AND
  - Participant is in sinus rhythm AND
  - Participant has an appropriate heart rate for therapy based on age:
    ▪ Aged 6-12 months: ≥ 105 beats per minute
    ▪ Aged 1-3 years: ≥ 95 beats per minute
    ▪ Aged 3-5 years: ≥ 75 beats per minute
    ▪ Aged 5 years and older: ≥ 70 beats per minute OR
- Participant aged ≥ 18 years:
  - Documented therapy with a beta blocker for 60 out of the past 90 days OR
  - Documented contraindications to beta blocker therapy AND
  - Participant has a left ventricular ejection fraction of 35% or less AND
  - Participant is in sinus rhythm AND
  - Participant has a resting heart rate of at least 70 beats per minute OR
- Approval based on clinical consultant review

**Denial Criteria**

- Therapy will be denied if all approval criteria are not met
- Documented history of severe hepatic impairment

**Required Documentation**

- Laboratory Results:  
- Progress Notes:  
- MedWatch Form:  
- Other: X

**Disposition of Edit**

Denial: Exception code “0682” (Clinical Edit)  
Rule Type: CE

**Default Approval Period**

3 months

**References**